#

Small caps

: 1220
ProMIS needs money to continue testing its Alzheimers drug / Photo: shutterstock
Small Caps·
Alzheimer's drug developer ProMIS loses over 20% of market capitalization in a day
JPMorgan advises holding 5-10% of small- and mid-cap stocks in a portfolio / Photo: Shutterstock
Small Caps·
Small-сap stocks could rise 15% in August – Fundstrat research head
Gilat Satellite wants to rise in the  in-flight connectivity market / Photo: shutterstock
Small Caps·
How Gilat Satellite aims to become a global IFC market leader
FTAI Aviation shares were supported by a tourism boom / Photo: Monty Rakusen/DigitalVision
Small Caps·
Stock that drove small-cap fund outperformance of S&P 500 spotlighted
Sterling Infrastructure shares have outperformed the S&P 500 by 24 percentage points a year over the last five years / Photo: Facebook/sterlinginfrastructure
Small Caps·
Forbes Advisor names top 10 small-cap stocks
The Charging Bull sculpture on Wall Street in New York / Photo: Shutterstock
Small Caps·
Capital Economics and Natixis have doubts about sustainability of small-cap rally
Perfect Corp. offers solutions for both men and women / Photo: beautygence.com
Small Caps·
How Perfect Corp. cashes in on virtual makeup and pretty selfies
Small-cap stocks are rising on expectations of a Fed rate cut / Photo: Reuters/Brendan McDermid
Small Caps·
Small caps triple S&P 500 gains over last month
Small-cap stocks had the biggest underperformance on record in the first half of the year / Photo: REUTERS / Brendan McDermid
Small Caps·
Small caps have worst run ever in first half of 2024
Shares of Daktronics are undervalued, Zacks says /Photo: daktronics.com
Small Caps·
Zacks advises investors to consider display manufacturer Daktronics
On Thursday, Magnificent Seven stocks had their worst day year-to-date Photo: Reuters/Brendan McDermid/
Small Caps·
Investors shift from Big Tech to smaller companies in anticipation of Fed rate cut
Citius Pharmaceuticals is preparing to go to market / Photo: Shutterstock
Small Caps·
Investors like momentum of lymphoma drug developer
Load more